Last reviewed · How we verify
Atorvastatin B
Atorvastatin B, marketed by Hanmi Pharmaceutical Company Limited, is a well-established drug in the lipid-lowering market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in the potential for increased competition as the patent expiration approaches.
At a glance
| Generic name | Atorvastatin B |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Systems Biological Assessment of Statin Effect on Vaccine Responses (PHASE4)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants (PHASE1)
- Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk (PHASE2)
- Concomitant Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Moderate and Moderate-to-severe Stroke (PHASE3)
- Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke (PHASE3)
- Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer (PHASE3)
- Secondary Prevention of Cardiovascular Disease in the Elderly Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin B CI brief — competitive landscape report
- Atorvastatin B updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI